Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Ivanova, S. Borisov, A. Ryzhov (Moscow, Russian Federation). Risk of serious adverse reactions during the treatment of new tuberculosis patients. Eur Respir J 2012; 40: Suppl. 56, 2603

Member's Comments

No comment yet.

Related content which might interest you: Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006 Adverse effects of treatment in HIV-associated tuberculosis patients in Iran Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts Year: 2011 Risk of tuberculosis in pediatric patients treated with biological agents Source: Virtual Congress 2020 – Aspects of acute and chronic airway infections in children Year: 2020 Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012 Adverse reactions to the tuberculosis treatment Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Adverse events during treatment for latent tuberculosis infection Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Risk Factors for tuberculosis in patients on anti-TNF treatment Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Treatment of latent tuberculosis infection: completion rates and adverse effects Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report Source: Eur Respir J, 54 (6) 1901522; 10.1183/13993003.01522-2019 Year: 2019 Adverse reactions of tuberculosis treatment in pacients with and without associated digestive disorders Source: Eur Respir J 2003; 22: Suppl. 45, 522s Year: 2003 Prevention and mechanism of undesirable adverse reactions in patients with pulmonary tuberculosis with extensive drug-resistance (XDR) combined with type 2 diabetes Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Risk factors of hepatotoxicity during tuberculosis treatment and management Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis I Year: 2008 Study of risk factors in relapses at patients with pulmonary tuberculosis. Their retreatment results Source: Eur Respir J 2001; 18: Suppl. 33, 467s Year: 2001 Treatment outcome and risk factors of death in elderly patients diagnosed as new cases of tuberculosis Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Risk factors for fatal tuberculosis among immunocompetent patients. Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017 Adverse events in the treatment of multidrug-resistant tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Spectrum of adverse drug reactions during MDR TB treatment Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Frequent adverse events during prolonged Bedaquiline treatment on XDR-tuberculosis patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019